We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Groups Use Neupogen Biosimilar Vote to Highlight Outstanding Issues
Groups Use Neupogen Biosimilar Vote to Highlight Outstanding Issues
An FDA advisory committee may have given its unanimous approval for a biosimilar application this month, but industry and patient groups contend the regulatory pathway still has many potholes and unanswered questions.